Charles Schwab Investment Management Inc Blueprint Medicines Corp Call Options Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding BPMC
# of Institutions
317Shares Held
60.6MCall Options Held
634KPut Options Held
691K-
Black Rock Inc. New York, NY6.45MShares$733 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.31MShares$717 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.25MShares$711 Million0.07% of portfolio
-
Wellington Management Group LLP Boston, MA4.18MShares$475 Million0.07% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.5MShares$284 Million6.2% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $6.79B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...